Selenium 	Placebo	Soluble vascular endothelial growth factor receptor-1 (Overall)	26637	26762	Effect of selenium supplementation v. placebo on soluble vascular endothelial growth factor receptor-1 (sFlt-1) concentration
Selenium 	Placebo	sFlt-1:PlGF	-1	-1	In participants in the lowest quartile of Se status at baseline, treatment with Se significantly lowered the concentration of sFlt-1 (P= 0·039) and halved the ratio of sFlt-1:PlGF, though the latter effect did not quite reach significance (P= 0·066); however, in all participants taken together, Se treatment had no effect on sFlt-1 concentration, PlGF concentration or sFlt-1:PlGF ratio.
Selenium 	Placebo	Soluble vascular endothelial growth factor receptor-1 (Overall)	-1	-1	in all participants taken together, Se treatment had no effect on sFlt-1 concentration, PlGF concentration or sFlt-1:PlGF ratio.
Selenium 	Placebo	Vascular cell adhesion molecule 1	-1	-1	All participants <TAB> 214 <TAB> 602 <TAB> 618 <TAB> 0·97 <TAB> 0·91, 1·04 <TAB> 0·407
Selenium 	Placebo	Placental growth factor	-1	-1	All participants <TAB> 233 <TAB> 240 <TAB> 0·97 <TAB> 0·78, 1·21 <TAB> 0·801
Selenium 	Placebo	sFlt-1:PlGF	-1	-1	All participants <TAB> 0·029 <TAB> 0·030 <TAB> 0·97 <TAB> 0·70, 1·36 <TAB> 0·875
Selenium 	Placebo	Soluble vascular endothelial growth factor receptor-1 (Overall)	-1	-1	All participants <TAB> 6·79 <TAB> 7·18 <TAB> 0·95 <TAB> 0·80, 1·12 0·511
Selenium 	Placebo	Placental growth factor	-1	-1	<td align="left" colspan="1" rowspan="1"><NEWLINE> <NEWLINE></td><td align="left" colspan="1" rowspan="1">All participants</td><td align="center" colspan="1" rowspan="1">233</td><td align="center" colspan="1" rowspan="1">240</td><td align="left" colspan="1" rowspan="1">0·97</td><td align="left" colspan="1" rowspan="1">0·78, 1·21</td><td align="left" colspan="1" rowspan="1">0·801</td>
Selenium 	Placebo	Soluble endoglin	-1	-1	All participants <TAB> 213 <TAB> 64·88 <TAB> 64·72 <TAB> 1·00 <TAB> 0·87, 1·16 <TAB> 0·973
